GNTA Key Statistics, Chart & Performance
The current stock price of GNTA is 1.93 USD. In the past month the price decreased by -24.61%. In the past year, price decreased by -63.24%.
GNTA Latest News, Press Relases and Analysis
GNTA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.55B | ||
| AMGN | AMGEN INC | 15.47 | 182.20B | ||
| GILD | GILEAD SCIENCES INC | 15.13 | 153.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.95 | 109.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.49 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 911.63 | 61.42B | ||
| INSM | INSMED INC | N/A | 44.06B | ||
| NTRA | NATERA INC | N/A | 32.66B | ||
| BIIB | BIOGEN INC | 10.76 | 26.43B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.97 | 20.42B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About GNTA
Company Profile
Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. The company is headquartered in Milan, Milano and currently employs 13 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.
Company Info
GENENTA SCIENCE SPA - ADR
Via Olgettina 58
Milan MILANO IT
Employees: 13
GENENTA SCIENCE SPA - ADR / GNTA FAQ
Can you describe the business of GENENTA SCIENCE SPA - ADR?
Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. The company is headquartered in Milan, Milano and currently employs 13 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.
What is the stock price of GENENTA SCIENCE SPA - ADR today?
The current stock price of GNTA is 1.93 USD. The price decreased by -4.46% in the last trading session.
What is the dividend status of GENENTA SCIENCE SPA - ADR?
GNTA does not pay a dividend.
How is the ChartMill rating for GENENTA SCIENCE SPA - ADR?
GNTA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for GNTA stock?
GENENTA SCIENCE SPA - ADR (GNTA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.44).
Would investing in GENENTA SCIENCE SPA - ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GNTA.
GNTA Technical Analysis
GNTA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to GNTA. GNTA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GNTA Financial Highlights
Over the last trailing twelve months GNTA reported a non-GAAP Earnings per Share(EPS) of -0.44. The EPS increased by 3.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.37% | ||
| ROE | -71.82% | ||
| Debt/Equity | 0.62 |
GNTA Forecast & Estimates
7 analysts have analysed GNTA and the average price target is 21.42 USD. This implies a price increase of 1009.84% is expected in the next year compared to the current price of 1.93.